Alnylam Pharmaceuticals Reports Strong 2025 Earnings with $3B Revenue, Led by 151% Surge in TTR Franchise

Alnylam Pharmaceuticals (ALNY) reported $3 billion in 2025 revenue, an 81% YoY increase, driven by a 151% surge in the TTR franchise. Q4 net product revenue reached $995 million, and the company launched Cyreli, an RNAi manufacturing platform. Alnylam also issued optimistic 2026 guidance, forecasting combined net product sales between $4.9 billion and $5.3 billion. Leadership emphasized the strength of the company's internal pipeline and the potential of products like Nrierran to drive operating margins into the mid-40s by 2030.